NO326458B1 - Substituerte benzofuranderivater, fremgangsmate for fremstilling derav, anvendelse av derivatene samt fremgangsmate for fremstilling av medikamenter - Google Patents

Substituerte benzofuranderivater, fremgangsmate for fremstilling derav, anvendelse av derivatene samt fremgangsmate for fremstilling av medikamenter Download PDF

Info

Publication number
NO326458B1
NO326458B1 NO20015857A NO20015857A NO326458B1 NO 326458 B1 NO326458 B1 NO 326458B1 NO 20015857 A NO20015857 A NO 20015857A NO 20015857 A NO20015857 A NO 20015857A NO 326458 B1 NO326458 B1 NO 326458B1
Authority
NO
Norway
Prior art keywords
mmol
nmr
methoxy
hours
solution
Prior art date
Application number
NO20015857A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015857D0 (no
NO20015857L (no
Inventor
Ulrich Jordis
Johannes Frohlich
Matthias Treu
Manfred Hirnschall
Laszlo Czollner
Beate Kalz
Stefan Welzig
Original Assignee
Sanochemia Pharmazeutika Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag filed Critical Sanochemia Pharmazeutika Ag
Publication of NO20015857D0 publication Critical patent/NO20015857D0/no
Publication of NO20015857L publication Critical patent/NO20015857L/no
Publication of NO326458B1 publication Critical patent/NO326458B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20015857A 2000-03-31 2001-11-30 Substituerte benzofuranderivater, fremgangsmate for fremstilling derav, anvendelse av derivatene samt fremgangsmate for fremstilling av medikamenter NO326458B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
AT2382001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (fr) 2000-03-31 2001-03-22 Nouveaux derives et analogues de la galanthamine

Publications (3)

Publication Number Publication Date
NO20015857D0 NO20015857D0 (no) 2001-11-30
NO20015857L NO20015857L (no) 2002-01-29
NO326458B1 true NO326458B1 (no) 2008-12-08

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015857A NO326458B1 (no) 2000-03-31 2001-11-30 Substituerte benzofuranderivater, fremgangsmate for fremstilling derav, anvendelse av derivatene samt fremgangsmate for fremstilling av medikamenter

Country Status (26)

Country Link
US (2) US7166588B2 (fr)
EP (1) EP1181294B1 (fr)
JP (1) JP2003529602A (fr)
CN (1) CN1380883A (fr)
AT (1) ATE263171T1 (fr)
AU (1) AU785385B2 (fr)
BG (1) BG65134B1 (fr)
BR (1) BR0105563A (fr)
CA (1) CA2368966A1 (fr)
CZ (1) CZ300160B6 (fr)
DE (1) DE50101827D1 (fr)
DK (1) DK1181294T3 (fr)
ES (1) ES2215885T3 (fr)
HK (2) HK1045990A1 (fr)
HU (1) HUP0202233A3 (fr)
IS (1) IS2287B (fr)
MX (1) MXPA01012275A (fr)
NO (1) NO326458B1 (fr)
NZ (1) NZ516302A (fr)
PL (1) PL202463B1 (fr)
PT (1) PT1181294E (fr)
RU (1) RU2241001C2 (fr)
SI (1) SI1181294T1 (fr)
SK (1) SK285909B6 (fr)
TR (1) TR200400857T4 (fr)
WO (1) WO2001074820A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
CA2479394A1 (fr) * 2002-03-25 2003-10-02 Ulrich Jordis Procedes pour la production de norgalanthamine, ses isomeres, sels et hydrates
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
WO2008022365A2 (fr) * 2006-08-24 2008-02-28 Sanochemia Ltd. Agent servant à influencer les effets de composés organophosphorés et utilisation de galanthamine, de ses dérivés et analogues pour la fabrication d'un tel agent
CN102007129B (zh) 2008-04-14 2014-05-07 神经动力生命科学公司 用作治疗人类脑疾病的前药的雪花胺衍生物
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
WO2011159759A1 (fr) 2010-06-15 2011-12-22 Ab Initio Technology Llc Chargement dynamique de calculs basés sur des graphes
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
CA2932763C (fr) 2013-12-05 2022-07-12 Ab Initio Technology Llc Gestion d'interfaces de graphiques de flux de donnees composes de sous-graphiques
DE112015003587T5 (de) 2014-09-02 2017-05-11 Ab Initio Technology Llc Spezifizieren von komponenten in graphbasierten programmen
CA2959389A1 (fr) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compilation de specifications de programme basees sur des graphiques avec groupage automatise de composantes graphiques sur la base de l'identification de connexions de port de donnees particulieres
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) * 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
BR9509406A (pt) * 1994-10-21 1998-11-03 Waldheim Pharmazeutica Ges M B Processo para a preparação de 4a,5,9,10,11,12,-hedaxidro-6h-benzofuro(3a,3,2,-ef) [2] benzazepina
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
HK1045990A1 (en) 2002-12-20
HUP0202233A2 (hu) 2002-11-28
JP2003529602A (ja) 2003-10-07
US20070027138A1 (en) 2007-02-01
SK285909B6 (sk) 2007-10-04
IS2287B (is) 2007-10-15
BG106155A (en) 2002-08-30
CN1380883A (zh) 2002-11-20
NO20015857D0 (no) 2001-11-30
BR0105563A (pt) 2002-04-02
US7166588B2 (en) 2007-01-23
AU4208501A (en) 2001-10-15
CZ300160B6 (cs) 2009-02-25
RU2241001C2 (ru) 2004-11-27
PL352638A1 (en) 2003-09-08
DE50101827D1 (de) 2004-05-06
NZ516302A (en) 2004-02-27
DK1181294T3 (da) 2004-08-02
IS6174A (is) 2001-11-23
SI1181294T1 (en) 2004-08-31
MXPA01012275A (es) 2003-06-24
EP1181294A1 (fr) 2002-02-27
EP1181294B1 (fr) 2004-03-31
NO20015857L (no) 2002-01-29
AU785385B2 (en) 2007-03-29
HUP0202233A3 (en) 2004-12-28
PL202463B1 (pl) 2009-06-30
CA2368966A1 (fr) 2001-10-11
CZ20014178A3 (cs) 2002-11-13
ES2215885T3 (es) 2004-10-16
US20030199493A1 (en) 2003-10-23
ATE263171T1 (de) 2004-04-15
WO2001074820A1 (fr) 2001-10-11
BG65134B1 (bg) 2007-03-30
PT1181294E (pt) 2004-07-30
SK17022001A3 (sk) 2003-02-04
HK1049832A1 (zh) 2003-05-30
TR200400857T4 (tr) 2004-06-21

Similar Documents

Publication Publication Date Title
US20070027138A1 (en) Derivatives and analogs of galanthamine
TWI707683B (zh) Glp-1受體促效劑及其用途
US20230271976A1 (en) Opioid receptor modulators
US11247987B2 (en) Inhibiting ubiquitin specific peptidase 30
CA2948161C (fr) Composes pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabete
US11266640B2 (en) Polycyclic compound acting as IDO inhibitor and/or IDO-HDAC dual inhibitor
US11866446B2 (en) Inhibitors of APOL1 and methods of using same
US11883393B2 (en) Compounds and methods for the targeted degradation of androgen receptor
RU2770437C2 (ru) Конденсированное циклическое производное, обладающее ингибирующей активностью в отношении mgat-2
US20230331720A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
TW201000479A (en) Tetrahydronaphthyridines and aza derivatives thereof as histamine H3 receptor antagonists
EP4208444A1 (fr) Dérivés hétérocycliques bicycliques et leurs utilisations en tant qu'agonistes du récepteur de l'orexine 2
TWI308568B (en) Chemokine receptor antagonists and methods of use therefor
US11352365B2 (en) Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
KR100768245B1 (ko) 신규한 갈란타민 유도체 및 유사체
EP3686196B1 (fr) Composé polycyclique agissant en tant qu'inhibiteur de l'ido et/ou en tant qu'inhibiteur double de l'ido-hdac
RU2769715C9 (ru) Агонисты рецептора glp-1 и их применение
WO2024094156A1 (fr) Composé amine et son utilisation
KR20230024886A (ko) 항바이러스 1,3-다이-옥소-인덴 화합물

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees